Across STEP 1 and 3 trials involving non-diabetic participants, semaglutide 2.4 mg exhibited average placebo-adjusted weight reductions of 12.4% and 10.3%, respectively, by week 68
Anti-inflammation effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients
With both of those things understood: for a patient who has done the clinical homework, confirmed the commitment terms directly with Novi, and is comparing cash-pay compounded options, Novi's all-in structure with coaching and unlimited clinician access may be relevant, especially if the promotional pricing, eligibility review, and pharmacy details are confirmed directly before enrollment
FDA approved : Approved for type 2 diabetes and weight loss (obesity)
The trials adhered to FDA guidance, Good Clinical Practice guidelines, and international standards for clinical research.